Q2 2020 Organogenesis Holdings Inc Earnings Call
At this time.
That's happened late in imaging only mode.
Please note that this conference call is being recorded and that recording will be available on the company's website for replay shortly.
For video game I would like to remind everyone that our remarks today may contain forward looking statements are based on the current expectations of management involve inherent risks.
And uncertainties that could cause actual results could differ materially from those indicated.
Including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission interesting I too want a risk factors.
The company's most recent annual and quarterly reports you are cautioned that took place undue reliance upon any forward looking statements, which speak only as of today, maybe although it may recall entirely due so from time to time the company undertakes no commitment to update.
Our revised the forward looking statements, whether as a result of new information future events or otherwise, except as required by applicable securities laws.
This call will also include references to certain financial measures that are not calculated in accordance with the generally accepted accounting principles or D.A.P.. We generally you refer to does not G.A.P. financial measures.
Concentrations of those non T.A.P. financial measures to the most comparable measures calculated and presented in accordance with D.A.P. are available in the earnings press release on the Investor Relations portion of our website.
I would now like turn the call over to Mr., Gary Yes, Q any senior Organogenesis Holdings, President and Chief Executive Officer. Please go ahead Sir.
Thank you.
Welcome everyone to Organogenesis Holdings second quarter 2020 earnings conference call.
I'm joined on the call today by CIMB Cunningham, our Chief Financial Officer.
Let me start with a brief agenda or what we won't cover during our prepared remarks I'll start with an overview of our revenue performance in the second quarter, including the improving business trends were experienced during the quarter and there is lot business that have performed extremely well despite the challenging operating environment.
After my opening remarks, Tim will provide you with a more in depth review of our quarterly financial results in the formal financial guidance, we reinstituted and this afternoon's press release as well as a summary of our balance sheet financial condition.
And then we'll open up the call for questions.
I'll begin with a review of our second quarter revenue performance.
We reported total revenue growth of 6% year over year in the second quarter.
Them by 8% growth in sales and our advanced wound care products, which offset a 5% decrease and sales of our surgical and sports medicine products compared to the prior year.
Our revenue results were well above expectations and exceeded the high end of our preliminary revenue range that we announced on July 15.
We believe our second quarter results weren't particularly impressive given the unprecedented level of uncertainty business disruption caused by the global pandemic beginning in mid March.
Simply stated we believe our second quarter revenue performance is a direct result from the organization's resilience in the face of these unprecedented challenges and the dedication of our employees to to our customers than patients.
Our growth in Q2 reflects a continuation of the key drivers of our growth, which we've talked about on each of our earnings call.
One of the investment that we've made to expand our salesforce all over the recent years strong execution of our commercial strategy and the benefits of our comprehensive portfolio and solutions, we offer the advanced wound care surgical sports medicine markets.
Offer a difficult start to the second quarter, and which year over year sales declined 29% for the month of April we saw business trends begin to improve and they as many healthcare facilities begin to began to reopened a reduced restrictions on access to their facilities and resume patient consultations and treatments.
By the end of May more than 80% of accounts that we service we're open compared to 70% at the end of April. We also saw early signs of improving activity at these accounts with roughly 50% accepting new patients at the end of may compared to less than 10% in in April.
Business trends improve significantly during the month of June as well as we ended the month with more than 90% of accounts opened in all of them accepting new patients. We also saw improving trends related to the percentage of accounts, allowing access to sales reps, which improved to 65% in june compared to less than 10% access.
At the end of April.
We were pleased to see the improving business trends in May and June and importantly, we were well positioned to drive strong growth as the environment improve given our competitive advantages in three areas.
One is our broad portfolio of products with strong brand recognition that allows us to treat patients needs throughout the wound healing process second our business mix. Both in terms of site of care and geographic regions favorite favorite areas that were less impacted.
By the disruptions caused by covert 19, and third our commercial strategy focused on leveraging multiple channels, new product introductions and brand loyalty to our products.
So in summary, after a difficult start to the quarter, where we saw sales declined 29% year over year in April our total sales for May and June together increased 24% year over year.
Notably the 24% increase in sales in May and June were driven by improving sales trends in both advanced wound care and our surgical sports medicine product groupings.
Which increased 24% and 20% year over year, respectively.
The growth trends in sales of advanced wound care products improved in each month of the second quarter and posted year over year growth in both May and June.
The growth trends on our surgical sports medicine business improved in May, but we're still down in the high single digits year over year in posted very strong year over year growth.
In June.
We're pleased with our second quarter performance the fundamentals of our business and strategy remains strong and we're well positioned to deliver strong operating and financial performance over the balance of 2020.
As such we reinstated our formal financial guidance, reflecting our expectations for total revenue growth of 5% to 6% in 2020, we believe it's noteworthy that this growth range is the same as the one we introduced as part of our initial 2020 revenue outlook on our Q4 2019 call.
Now back in March before the global pandemic disrupted the U.S. operating environment.
So with that let me turn it over to Tim for a review of our financial results for the second quarter and our balance sheet.
Thank you Gary I Hope I will begin with review of our second quarter financial results.
Unless otherwise specified all growth rates reference during my prepared remarks, I want a year over year basis.
Revenue for the second quarter 2020.
69 million.
Appeared to 64.9 million for the second quarter of 29 team an increase of 4 million were 6%.
Second quarter revenue results came in above the high end of the preliminary revenue range provided on July 15th.
Revenue from advanced wound care products for the second quarter 2020.
59.7 million compared to revenue of 55.2 million for the second quarter 2019, an increase of 4.5 million or 8%.
Revenue from advanced wound care products represented 87% of total revenue in the second quarter of Twentytwenty compared to 85% of total revenue in the prior year period.
Revenue from surgical sports medicine products for the second quarter of 2020 was 9.2 million compared to 9.7 million, but the second quarter of 2019 decreased 8.5 million were 5%.
Revenue from surgical sports medicine products represented 13% of total revenue to second quarter 2020, compared to 50% of total revenue in the prior year period.
Revenue from pure play products or the second quarter 2020.
Was 28.5 million compared to 29.7 million in the second quarter 2019.
Decreased 1.2 million of 4%.
Revenue from pure play products represented approximately 41% of total revenue second quarter of 2020 compared to 46% of total revenue in the second quarter 2019.
As of June Thirtyth Twentytwenty, we had approximately 285 direct sales representatives compared to 265 at year end to end 2019.
Approximately 160 independent agencies compared to 160, a year in 2019.
Gross profit for the second quarter 2020 was 48.9 million compared to 45.5 billion for the second quarter 2019, an increase of 3.4 million or 8%.
Gross profit margin for the second quarter 2020 was 71% of revenue.
Compared to 70% of revenue.
Second quarter 2019.
The increase in gross profit gross profit profit margin resulted from increased sales volumes, primarily strengthen our advanced wound care products and changes in product mix.
Operating expenses for the second quarter 2020 were 51.2 million compared to 52.8 million for the second quarter 2019, a decrease of 1.7 million a 3%.
Sure.
Recent operating expenses in the second quarter 2020, as compared to the second quarter 2019 was driven primarily by lower selling general and administrative expenses, which decreased to 46.5 million compared to 49 million second quarter 2019, a decrease of 2.5 million or five or 5%.
The decrease in selling general administrative expenses is primarily due to.
Reduced travel and marketing programs and mid coping 19 related travel restrictions.
The decrease in amortization associated with intangible assets.
And a decrease in legal consulting fees and other costs associated with the ongoing operations of our business.
These decreases in SGN expenses were offset partially by an increase in expenses due to additional how to head count primarily in our direct salesforce.
R&D expense was 4.7 million for the second quarter 2020, compared to 3.9 million in the second quarter 2019, and increase a point 8 million were 21%.
Increase in R&D was driven by additional headcount and continued investment in clinical programs and our product pipeline.
Total operating expenses for the second quarter 2020.
51.2 million.
6.9 million or 12% decrease from 58 million of operating expenses in the first quarter 2020.
6.9 billion reduction in operating expenses this quarter represents better than expected performance against versus our stated goal to reduce expenses by five to 6 million in the quarter. Jack third direct result of our proactive efforts to identify and implement cost savings measures as a result of a rapidly evolving.
Your vote environment and continued uncertainty, resulting from the impact of Cobot 19.
These cost savings measures were primarily related to discontinuing all non essential services and programs.
Instituting controls on discretionary spending, including travel event marketing and temporary delays in some clinical spending.
Operating loss for the second quarter, 2020 was 2.3 million compared to an operating loss of 7.3 million for the second quarter 2019, a decrease of 5.1 million or 69%.
Total other expenses for the second quarter, 2000, 22.9 million compared to 2.3 million for the second quarter 2019, an increase of point sixmillion or 25%. The increase was driven primarily by higher interest expense related to increased borrowings borrowings compared to the prior.
Your period.
Net loss for the second quarter, 2020 was 5.2 million or 5% five cents per share compared to a net loss of $9.6 billion or 11 cents per share for the second quarter 2019, a decrease of 4.5 million were 46%.
Adjusted EBITDA of 274000 for the second quarter 2020, compared to announce adjusted EBITDA loss of 4.8 million for the second quarter 2019, an increase of 5.1 million or 106%.
We have provided a full reconciliation of our adjusted EBITDA results in our earnings release form 8-K, and form 10-Q, all of which were filed with the FCC. This afternoon.
Turning to a brief review of our financial results. The six months ended June Thirtyth Twitch 20.
Net revenue for the six months ended June Thirtyth 2020 was 130.7 million compared to 122.1 million for the first six months of 2019, an increase of 8.6 million or 7%.
The increase in net revenue was driven by an increase of 8 million or 8% net revenue advanced wound care products and an increase of 8.7 billion or 3% and net revenue of surgical sports Med sports medicine products compared to the prior year.
Revenue a pure applied products for the six months ended June Thirtyth 2020 to 61 million.
Compared to 55.1 million.
For the first six months of 29 team, an increase of 5.9 billion or 11%.
Net revenue a pure apply products represented approximately 47% of net revenue for the six months ended June Thirtyth 2020, compared to 45% for the first six months to 2019th.
Gross profit was the first six months.
For the six months ended June Thirtyth, 2020 was 91.9 million or 70% of revenue compared to 85.6 million, where 70% of net revenue for this first six months or 29 team an increase of 6.2 million were 7%.
Operating loss for the six month ended June Thirtyth 2020.
17.3 billion compared to an operating loss of 19.4 million. The first six months of 29 team a decrease of 2.1 million or 11%.
Net loss for the first six months.
For the six months ended June Thirtyth, 2020 was 21.5 million or 21 cents per share compared to net loss of 25.3 million were 28 cents per share for the first six months of 29 cheap.
Turning to the balance sheet.
As of June Thirtyth Twentytwenty, the company at 40.5 billion cash 115.3 million in debt obligations.
16.3 million will capital lease obligations compared to $60.2 million cash and 100.6 million a debt obligations of which 17.5 million were capital lease obligations as of December 30, Onest 2019.
The net change in cash of approximately 19.6 million, but the six months ended June Thirtyth 2020 is driven by 13.1 billion of cash provided by financing activities offset by 26.6 million of cash used in operating activities at $6.1 million of cash used in.
Investing activities during the period.
As of June Thirtyth 2020, we were in compliance with the financial covenants under the credit agree with Silicon Valley Bank at quarter end, we had 60 million outstanding borrowings under the term loan facility and $39.4 million borrowings on the revolving facility.
We expect that our cash on hand as of June Thirtyth 2020 cash flows from product sales will be sufficient to fund our operating expenses capital expenditure requirements and debt service payments for at least the 12 month following our filing of our 10-Q.
Turning to review of our 2020 revenue guidance.
As detailed in our press released this afternoon, we are reinstituting fiscal year 2020 revenue guidance originally issued on March nine 2020.
The 12 months ended December 31st 2020, the company now expects.
Revenue of between 273 million and 277 million representing growth of approximately 5% to 6% year over year as compared to net revenue of 261 million for the 12 months ended December 30, Onest 2019.
The 2020 net revenue guidance range assumes net revenue from advanced wound care products of between 236 million to 238 million representing growth of approximately 7%, 7% to 8% year over year as compared to net revenue was 221 million for the 12 months ended December 31.
2019.
Net revenue from surgical sports medicine products of between 37.039 billion, representing a decrease of approximately 3% to 8% year over year as compared to net revenue of $40 million for the 12 months ended December 30, Onest 2019.
Net revenue from the sale a pure play product of between 108 million and 110 million, representing a decrease of approximately 30% to 50% year over year compared to net revenue of 127 million.
For the 12 months ended December 30, Onest 2019.
In addition to the former revenue guidance were losses also like to provide a few additional considerations when evaluating our growth expectations for fiscal year 2020.
You may recall that we introduce additional assumptions supporting our fiscal year 2020 revenue guidance through our Q4 2019 call in March.
This additional color is intended to help the investment community better understand the assumptions supporting our revenue expectations for 2020.
First the largest contributor to our total company net revenue growth in fiscal year, Twentytwenty will be sales of our amnion products, which at the midpoint of our full year range assumes Andy amnion growth were approximately 60% year over year in Twentytwenty.
Second we expect sales of our remaining non pure apply non amnion products, which collectively form the group, we call Pmeight and other to decrease at the midpoint of the range approximately 8% year over year Twentytwenty.
Expected year over year decline of non pure apply non amnion products is larger result of the softer sales performance in Q2.
Due to the covert 90 related business disruptions.
Third the midpoint of our fiscal year Twentytwenty net revenue guidance assumes per applied sales declined approximately 14% this year, which refresh which reflects our expectation that pure applied sales with decreased by approximately 45% to 50% year over year in the fourth quarter.
Twentytwenty following the transition to the high cost bundle beginning on October Onest Twentytwenty.
With that operator, I'll turn the call back over to you.
Thank you.
Yeah like you asked the question. Please take note by pressing star one on your telephone keypad.
You are using a speaker phone. Please make sure your mute function is there though.
Your signal to reach our equipment.
We do as you limit yourself to one question and one follow up.
If you would like to US additional question, we invite you to add your so did you again by pressing star one.
And our first question will come from.
Matt Miksic.
Sir Your line is now open.
Great. Thanks, so much for taking my questions and congrats on what was a pretty strong quarter in a pretty tough environment. In fact, I'm looking at the growth rate in AFFO not mistaken it might be it might be the best.
Planned growth rate.
In our universe. This quarter, so I know, 6% wasn't where you started out aiming at for the year, but congrats on on a pretty pretty poor handling Q2 pretty well.
Thank you. Thank you ma'am.
You bet. So there's a lot to follow up on but I wanted to focus on.
A couple of things one.
Was the sort of the strength and amnion and.
What what you can say maybe about.
About.
Your supply levels.
The the trajectory of that growth in the quarter and maybe our deferred across a across.
Sites of care.
And then.
Distressed there's too much but.
You know theres very competitive landscape is changing at the anticipated changing you know one of your old friends is getting refunded and and you know recapitalized and expect it gets to be back out in the market and how we should think about that and then I have one follow up.
Sure.
Right got our amnion I think.
What's important is.
Relaunched DEFINITY, which certainly had a significant impact on the quarter.
On product selling extremely well and also our strategy of diversifying our sites of care and our offerings and those sites of care. So as we focused on the office that allowed.
As to continue to sell.
Not only just our Amiens, but also our other products that are designed for that site of care. So we're pretty pretty excited about how our amnion to performing excited about the relaunch of affinity.
Yes, we have a new manufacturers our supply of affinity is much stronger than it ever was continuing to build that capacity.
As we go forward as demand continues to increase so sites of care were important for affinity as well as.
Obviously the.
The other products that we have in the supply that we have.
On the competitive landscape I'm really havent seen much of a change and yet though other competitors are certainly stepping back in.
You know affinity is the only fresh amniotic product in the space, we're pretty excited about that pure reply is still very strong product.
Particularly in the office and outpatient setting so.
We're pretty excited and pretty confident that our portfolio will withstand any anything that we see in the competitive environment today.
The other thing that's interesting is we still have access they only have access to 65% of the one care centers, but we virtually have been connected to about 100% of our customers. So.
We've continued to build out brand and our relationships. During this difficult time, and we think that will pay dividends for us down the road as well.
Great. That's helpful color and then that just on pure apply I'm sure you'll get some other questions on this but but you know given that.
Looking at the down 45 to 15 Q4 and down.
14 for the year.
You know how am I know you started the year with with the with the strategy in mind.
To expand the number of skews under that brand.
And sort of.
You know, but buffer that business a little bit from the kinds of sharp declines that might be implied by by the expiration of the pass through.
Reimbursement you like is what it would have you learned so far.
Maybe how has your thinking changed if at all and maybe what what kinds of assumptions are baked into that you know that down 14 at this point.
Sure I'll start and Tim Schoen, a jump and that's true that's fine. So we have launched additional skews we have expanded.
The pure play offering and the number of accounts in the office studying utilizing pure apply so that will have significant impact and holding the brand and product. We've also launched our X T line extension of pure apply which is selling very well, we just recently launched that.
And we expect that product continued to grow to help offset any decline in pure reply sales Tim.
No I think there the only thing I would add to that Matt is that.
We started the year with pure apply being down 40 to 45. So I think you really hasn't evolved or changed and we're pleased that to the line extensions.
X T as Gary mentioned, but the majority of the declines really just to the effect of cobot.
Okay. All right that's helpful and I guess this just done just to clarify Gary your comment on XT recently launched.
Is that does that affect I guess on that on the potential.
Potential growth or decline in pure play still sort of.
You know uncertain or what are your assumptions in terms of the success of that product.
Right now, we're very confident in the product, it's selling extremely well weve thoughtfully launched it in only certain regions of the country.
And is performing above our expectations at this point. So we think it'll be a strong contributor to help offset any ASP impact on the larger sizes that we have.
That are impacted by.
Pass through.
So.
We're very confident as Tim mentioned Q4 is impacted not just by the ASP, but.
Back to Covance and rebounding from that.
But we think XT will be a strong contributed to the growth of pure apply post pass through.
Excellent very helpful. I'll hop back in queue. Thanks, so much.
Thank you.
Thank you and our next question from the line of Ryan Zimmerman, Sir Your line is now open.
Great. Thank you and let me I feel Matt sentiments really a strong performance in light of everything.
So maybe just to begin Gary and Tim I'm, just curious you know with with everything that happened in the second quarter and how clinics reopened I was wondering how much you.
How much impact maybe either backlog.
For a surge occurred in June and kind of how you're thinking about that.
At all into the third quarter, and then and then I have a follow.
We really didnt see a big impact of backlog.
In June.
At all certainly not in advanced wound care and.
Not as a little bit more maybe in the surgical sports medicine area, but.
On the surgical sports medicine side, 75% of our business isn't sort of the non metropolitan areas. So they did fairly well once we got through May.
They rebounded extremely well in June so there was some backlog there, but we don't have a lot of backlog built into our Q3 or Q4.
Got it that's helpful Gary and then.
The rep hiring did it continued increase but at the same time productivity levels improve sequentially, which is which is quite impressive given given what.
Other peers have seen this quarter so.
Can you talk to us about your longer term views on what the appropriate rep levels are maybe you know some thoughts around productivity in kind of where you think you can take that.
To kind of help us frame out continued expansion or salesforce.
While certain an area. That's it's an area we focus a lot of attention on and it speaks to our portfolio as we get deeper and you've heard me say this on other calls we continue to get deeper and deeper into our accounts.
As we utilize our portfolio along with New addition, such as affinity which is a re addition, and pure play XT, which is a new addition.
We expect that to continue to grow and.
Our expectations for reps, we we'd like to get the 303 15.
10, probably at the end of the year, we'd like to see our agencies go up to around 170 to 180, and we expect productivity improvements in each of those areas, both the agencies and our direct reps.
Each year as we launch new products. So it's important when you for us that we strategically put product offerings in different sites of care one to maximize the potential of the product, but also not cannibalize other products. So we're continuing to improve the productivity of our sales rep.
Yes.
So we are guide is always been a million dollars per rep.
Exceed that and we will continue to exceed that but our goal is to improve that you know every year.
Yeah.
That's very helpful. And then is the last one for me I'll hop back in Q.
With with the dynamic that's occurring in the fourth quarter with pure play I Wonder if you could maybe talk to us about your underlying assumptions for unit growth in spite of the changes to reimbursement prepare apply and how that may.
Play out or or kind of what you're hoping for into into the next year.
From an underlying basis, thanks for taking the questions and and again very strong performance right sure. Thank you.
We certainly expect units to grow next year pure apply.
In Q4, and I'll I'll defer to Tim.
We expected to be a slight decline that's typically what we experienced so ill pass through only affects our larger size products, which for us too.
So those sales will decline.
And we will eventually see the units increase as.
Those large and wounds referred to some of the products offerings that will add to the bundle that can handle those homes and because of our office strategy. There our solutions in the office for those larger loans, but it will take a little time, it's usually a quarter and a half when we start to see the units to grow beyond the previous year. So.
Quarter over quarter, and a half decline in units, but then you will see growth in the office and you'll see more NHL PD, which is the outpatient setting as those larger ones utilize some of our new offerings that will be.
We'll be putting out in October.
Thank you.
Thank you and next question coming from the line of Richard Newitter.
Sir Your line is now open.
Hi, Thanks, guys.
Congrats.
On on delivering growth and expecting growth.
And actually providing an outlook you certainly we'll send out this quarter.
A couple of questions here, just on affinity and the MBS portfolio broadly to if you can comment on that.
What surprised you most.
I'd say in the quarter if anything.
And with respect to affinity accounts and utilization relative to maybe what your expectations would have been for the relaunch of this school using it and where an existing customers or what's the mix of the the customer base for that product that particular sure. It's primarily in the office right now so we've strategically launched it in.
Certain areas of the country in the office only.
And.
We have historically users of the product as you know we the product was sold in 2018, but we've been able to add additional customers at a very rapid rate. So.
The product is selling extremely well it's exceeded our expectations at this point in time.
And we'll continue to expand the office offering as capacity expands.
Great.
And I'm, just beyond and you had DEFINITY anything else.
Folio that that surprised you positively or negatively in particular during the quarter than I have one follow up well what was interesting is what we call RPM and other products like Apligraf and Dermagraft mature.
The gold standard in wound care in our opinion and certainly the anchors that of our wound care advanced wound care market grew extremely well in fact for some some of our higher growers.
And what we learned is what we believed as the brand equity of those products and particularly in a time of crisis going back to something that.
You know was works you know, it's going to be reimbursed, it's covered by 1500 private payers.
It just was a migration back to those products immediately.
That was a bit of a surprise.
Our strategy of moving more into the office.
We weren't surprised that.
Owns and other procedures moved to the office when hospitals and outpatient centers will close but the pace.
In which they moved.
It was a bit surprising to our advantage so.
Fortunately our strategy.
Paid dividends for us encoded actually helped drive that strategy. So I think those at a too surprising things.
Hi.
The launching of two products, we launched pure play XT and affinity in the midst of a crisis and both have exceeded our expectations.
Affinity is already beyond the the run rate that we exited in 2018.
In a very short period of time so.
I think those things the brands the strong brands RPM, a products and extremely well.
The office space business grew even faster than we thought and launching two new products in the middle of all of this.
Went very well.
Great and if you would the.
No I appreciate that you have different.
Different mixes.
Capital is based.
Accounts, and maybe kind of more rural accounts, but in areas that are seeing surges or resurgence of the buyers Im just curious you can comment on any any friends or potentially signed up for three or.
Or if not.
It would be helpful.
Just given that there's different trends that are starting to emerge across the country. Thanks, sure well would definitely sand trends.
Negative trends in the Texas area, Arizona.
And as well as in the Miami area. So we're seeing some of those trends. Fortunately again, we're not in the metropolitan areas like Miami.
Or some Houston Dallas areas, but we are starting to feel a little bit of it in those markets, we're seeing a little bit of a slowdown. So we've been it's one of the reasons were a little cautious and our guidance on the surgical sports medicine business for the second half of the year.
But.
Most of the business that we have as I said is in the non metropolitan areas. So we don't expect to see a significant decline if there is a large rebound.
Thank you Covance.
Thank you.
Again, if you like does it what's Jim we signaled by pressing star one all your telephone keypad, if you're using it speakerphone. Please make sure. Your mute function is turned up to allow you a signal to reach our equipment, we do as yet you limit yourself to one question and one follow up.
If you would like to lots of question.
Additional questions. We invite you to add yourself to the Q again by pressing star one.
I know next question from the line of Steven.
Which ma'am your line is now open.
Thank you hi, guys and congratulations on the quarter.
Just wanted to follow up on the last question.
Prior question around backlog.
The May June grow because was very impressive.
You did mention Gary that you didnt see the growth being driven by backlog.
Looking forward do you see deferred procedures day from that late March and April timeframe, there for being incremental tailwind still to come and potential upside driver.
We do more us on the surgical sports medicine side, but we do see that as a potential tailwind.
For us and to the end of Q3 and more so in Q4.
Moreover, we don't see a lot of backlog in the advanced wound care side, because many of those wounds I think moved to the office because we're seeing a significant growth in the office. We are clearly taking share in the office, but I believe a lot of those ones are ones that would've been treated and.
Vance wound care outpatient center are being treated in the office. So I think we've absorbed some of that there should be some but not significant on the advanced wound care side.
Yeah.
Great. Thanks, Gary and then just secondly on on the pipeline.
Yeah, we're getting a little closer I think two to translate.
Launch I think you've talked in the medium term here.
How should we be thinking about your preparations for launch there and what kind of work need needs to get done in.
And then also just wanted to ask you.
With respect to renew.
Whether that.
That trial is restarted as well.
So regarding tranche site, which were looking to launch end of.
2021 at this point so our preparation is.
We need to build a direct salesforce that will be in the process of starting we think it's a very concentrated market one that we think we conserve.
Small group of sales folks 28, I think a 128 centers that we'd be calling on.
Control about 40% of the market.
So that's important and so thats part of the strategy. We're also still working on translate to get the manufacturing process.
Which as you know, we reengineering that process to keep the capacity where it needs to be to meet demand, but also to keep the margins where they need to be so that work is still going on.
So building the Salesforce and continuing to make sure the manufacturing processes as robust as with what our focus is.
Regarding renew.
Renew most of the clinical work for renew is on hold right now partly because of spending holds.
That we put on the product.
Project because of co bid, we now expect to ramp that back up at the end.
During Q3 and expect to start that trial in Q4. This year Q1 of next year.
Called it has had an impact generally on all of our clinical work in some way shape or form.
But we expect Q4 Q1 that renewed trial.
Understood.
Thanks, Gary appreciate it.
Sure.
Thank you.
Currently showing no remaining questions into Q.
This time.
That does conclude our conference for today. Thank you for your participation.
Thank you.
[music].